659736-46-6

Upstream product

• 4133-35-1 6-bromo-2-tetralone 
• 151-50-8 potassium cyanide 
• 506-87-6 ammonium carbonate 
• 143-33-9 sodium cyanide 
• 773837-37-9 sodium cyanide 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 37859-24-8 2-(4-bromophenyl)acetyl chloride 

Downstream Products

• 690254-43-4 methyl 2-amino-1,2,3,4-tetrahydro-6-bromo-2-naphthalenecarboxylate 
• 690254-48-9 (S)-2-(tert-butyloxycarbonyl)amino-1,2,3,4-tetrahydro-6-bromo-2-naphthalenecarboxylic acid 
• 690254-49-0 benzyl (S)-2-(tert-butyloxycarbonyl)amino-1,2,3,4-tetrahydro-6-bromo-2-naphthalenecarboxylate 
• 659736-91-1 2-amino-6-bromo-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid 

Relevant academic research and scientific papers

HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (where variables R2, R7, D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, R6, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

BICYCLIC SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B, E1, E2, E3, E4, E5, G1, G2

SPIROHYDANTOIN ARYL CGRP RECEPTOR ANTAGONISTS

Compounds of formula (I); (wherein variables A1, A2. A3, A4, A5, A6, A7, B3 E1, E2, E3, E4, E5, G1, G2 and R.6 are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, T, U, V, W, X, Y, Z, R4, R5a?, R5b/su

ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also dire

MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Synthesis of α,α-disubstituted 4-phosphonophenylalanine analogues as conformationally-constrained phosphotyrosyl mimetics

Syntheses of N-Boc (S)-4-(diethylphosphono)-(α-methyl)phenylalanine [Boc-(α-Me)Phe(4-PO3Et2)-OH] (9) and N-Boc (S)-2-amino-6-(diethylphosphono)tetralin-2-carboxylic acid [Boc-Atc(6-PO 3Et2)-OH] (18) are reported

BENODIAZEPINE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also dire

Structure-activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: Histidine substitution

Systematic substitution of His6 residue using non-selective hMC4R pentapeptide agonist (Bu-His6-DPhe7-Arg8-Trp9-Gly 10-NH2) as the template led to the identification of Bu-Atcsu